News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,060 Results
Type
Article (13818)
Company Profile (101)
Press Release (252141)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88068)
Career Advice (465)
Deals (15345)
Drug Delivery (67)
Drug Development (36607)
Employer Resources (49)
FDA (6299)
Job Trends (6202)
News (150257)
Policy (14045)
Tag
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (36)
Alliances (23238)
ALS (37)
Alzheimer's disease (394)
Antibody-drug conjugate (ADC) (42)
Approvals (6339)
Artificial intelligence (112)
Autoimmune disease (9)
Automation (4)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (22)
Brain cancer (16)
Breast cancer (83)
Cancer (645)
Cardiovascular disease (72)
Career advice (409)
Career pathing (12)
CAR-T (23)
Cell therapy (90)
Cervical cancer (4)
Clinical research (30946)
Collaboration (352)
Compensation (159)
Complete response letters (17)
COVID-19 (759)
CRISPR (22)
C-suite (128)
Cystic fibrosis (37)
Data (667)
Denatured (15)
Depression (10)
Diabetes (83)
Diagnostics (1325)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (61)
Drug pricing (66)
Drug shortages (12)
Duchenne muscular dystrophy (37)
Earnings (32231)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37598)
Executive appointments (400)
FDA (6741)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (216)
Gene editing (40)
Generative AI (9)
Gene therapy (101)
GLP-1 (350)
Government (1301)
Grass and pollen (3)
Guidances (23)
Healthcare (3564)
Huntington's disease (4)
IgA nephropathy (12)
Immunology and inflammation (35)
Indications (14)
Infectious disease (794)
Inflammatory bowel disease (56)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (48)
Interviews (59)
IPO (5880)
IRA (29)
Job creations (2051)
Job search strategy (373)
Kidney cancer (6)
Labor market (12)
Layoffs (181)
Leadership (4)
Legal (3433)
Liver cancer (19)
Lung cancer (87)
Lymphoma (57)
Machine learning (2)
Management (16)
Manufacturing (163)
MASH (34)
Medical device (1277)
Medtech (1279)
Mergers & acquisitions (9675)
Metabolic disorders (267)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (8)
Neuroscience (584)
NextGen: Class of 2025 (1586)
Non-profit (595)
Now hiring (8)
Obesity (152)
Opinion (119)
Ovarian cancer (22)
Pain (54)
Pancreatic cancer (15)
Parkinson's disease (47)
Partnered (7)
Patents (121)
Patient recruitment (30)
Peanut (10)
People (28988)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8055)
Phase II (13092)
Phase III (11748)
Pipeline (471)
Policy (72)
Postmarket research (1401)
Preclinical (3230)
Press Release (25)
Prostate cancer (48)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (170)
Real estate (2637)
Recruiting (17)
Regulatory (10141)
Reports (14)
Research institute (566)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (37)
Series A (38)
Series B (13)
Service/supplier (3)
Sickle cell disease (32)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1629)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (32)
The Weekly (30)
Vaccines (156)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (4)
Date
Today (65)
Last 7 days (279)
Last 30 days (898)
Last 365 days (11727)
2025 (3918)
2024 (12501)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10593)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (57)
Arkansas (3)
Asia (20150)
Australia (2616)
California (1783)
Canada (930)
China (248)
Colorado (71)
Connecticut (70)
Delaware (61)
Europe (39521)
Florida (341)
Georgia (39)
Idaho (9)
Illinois (202)
India (16)
Indiana (137)
Iowa (1)
Japan (96)
Kansas (58)
Kentucky (13)
Louisiana (1)
Maine (2)
Maryland (264)
Massachusetts (1537)
Michigan (30)
Minnesota (95)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (8)
New Hampshire (6)
New Jersey (787)
New Mexico (7)
New York (533)
North Carolina (404)
North Dakota (2)
Northern California (733)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (460)
Puerto Rico (8)
Rhode Island (10)
South America (503)
South Carolina (2)
Southern California (748)
Tennessee (34)
Texas (237)
United States (7459)
Utah (34)
Virginia (78)
Washington D.C. (31)
Washington State (123)
Wisconsin (17)
266,060 Results for "censa pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
PTC Therapeutics to Acquire Censa Pharmaceuticals
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has entered into an agreement to acquire Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth.
May 6, 2020
·
7 min read
Deals
PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has successfully completed the acquisition of Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and ot
June 1, 2020
·
5 min read
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
Drug Development
Censa Pharmaceuticals Announces CNSA-001 Met Primary and Secondary Endpoints in Phase 2 Trial in Patients with PKU
Censa Pharmaceuticals, Inc. (‘Censa”) today announced positive results from its Phase 2 trial for CNSA-001 (sepiapterin), a potential new medicine for the treatment of phenylketonuria (PKU)
December 3, 2019
·
2 min read
Mergers & acquisitions
Taiho Pharmaceutical Buys ADC Partner Araris for up to $1.1B Total
Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.
March 17, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
X4 Pharmaceuticals Announces Reverse Stock Split
April 24, 2025
·
6 min read
Press Releases
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
April 8, 2025
·
4 min read
Press Releases
Hemogenyx Pharmaceuticals PLC Announces Final Results
April 29, 2025
·
1 min read
Press Releases
Conduit Pharmaceuticals Announces Leadership Changes
April 16, 2025
·
5 min read
Press Releases
Azurity Pharmaceuticals Completes Acquisition of Covis Pharma
March 17, 2025
·
4 min read
1 of 26,606
Next
